Abdominal and pelvic complications of nonoperative oncologic therapy

Radiographics

Volumn 34, Issue 4, 2014, Pages 941-961

  Viswanathan, Chitra ^a   Truong, Mylene T ^a   Sagebiel, Tara L ^a   Bronstein, Yulia ^b   Vikram, Raghunandan ^a   Patnana, Madhavi ^a   Silverman, Paul M ^a   Bhosale, Priya R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Virtual Radiologic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMEN; ADULT; ADVERSE EFFECTS; AGED; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTESTINAL DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PELVIS; PRESCHOOL CHILD; RADIATION INJURIES; RADIOGRAPHY; SPLENIC DISEASES; VASCULAR DISEASES;

ABDOMEN; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; HUMANS; INTESTINAL DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PELVIS; RADIATION INJURIES; RADIOTHERAPY; SPLENIC DISEASES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES;

EID: 84904353607     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.344140082     Document Type: Article

References (71)

1. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60(4):222-243.
2. Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005;55(2): 117-134.
3. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7(8):1034-1044.
4. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009;16(2):137-144.
5. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24(13): 2065-2072.
6. Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013;2013:815105.
7. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. RadioGraphics 2006;26(6): 1637-1653.
8. Fennessy FM, Mortele KJ, Kluckert T, et al. Hepatic capsular retraction in metastatic carcinoma of the breast occurring with increase or decrease in size of subjacent metastasis. AJR Am J Roentgenol 2004;182(3):651-655.
9. Shirkhoda A, Baird S. Morphologic changes of the liver following chemotherapy for metastatic breast carcinoma: CT findings. Abdom Imaging 1994;19 (1):39-42.
10. Donadon M, Vauthey JN, Loyer EM, Charnsangavej C, Abdalla EK. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRIbevacizumab for colorectal liver metastases. World J Gastroenterol 2006;12(40):6556-6558.
11. Robinson S, Manas DM, Pedley I, Mann D, White SA. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol 2011;20(2):57-72.
12. Cefalo MG, Maurizi P, Arlotta A, et al. Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies. Paediatr Drugs 2010;12(5):277-284.
13. Agarwal V, Sgouros J, Smithson J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Reports 2008;2:227.
14. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15(3): 460-466.
15. Sohaib SA. Extrapulmonary complications of bone marrow transplantation. Br J Radiol 2002;14(4): 278-284.
16. Erturk SM, Mortelé KJ, Binkert CA, et al. CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol 2006;186(6):1497-1501.
17. Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003;78(5):589-598.
18. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010;56(4):430-439.
19. Hubert C, Sempoux C, Humblet Y, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) 2013 Jan 18. [Epub ahead of print]
20. Xu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Rev 2009 Mar 13. [Epub ahead of print]
21. Masood N, Shaikh AJ, Memon WA, Idress R. Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 2008;1(1):418.
22. Elliott MA, Mesa RA, Tefferi A. Adverse events after imatinib mesylate therapy. N Engl J Med 2002;346 (9):712-713.
23. Lubner M, Menias C, Rucker C, et al. Blood in the belly: CT findings of hemoperitoneum. Radio-Graphics 2007;27(1):109-125.
24. Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010;28(15):2549-2555.
25. Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009;8(4):225-230.
26. Levy DW, Rindsberg S, Friedman AC, et al. Thorotrast-induced hepatosplenic neoplasia: CT identification. AJR Am J Roentgenol 1986;146(5): 997-1004.
27. Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of uncommon chemotherapy-induced emergencies. Lancet Oncol 2011;12(8):806-814.
28. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009;7(9):600-606.
29. Butt W, Saadati H, Saif MW. Oxaliplatin-induced pancreatitis: a case series. Anticancer Res 2010;30 (12):5113-5115.
30. Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. JOP 2010;11(3):283-284.
31. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006;13(5):635-644.
32. Tavakkolizadeh A, Shen R, Abraham P, et al. Glucagon-like peptide 2: a new treatment for chemotherapy induced enteritis. J Surg Res 2000;91(1):77-82.
33. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009;2009:567486.
34. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999;86(7):1129-1134.
35. Velanovich V, LaPorta AJ, Garrett WL, Richards TB, Cornett PA. Pseudomembranous colitis leading to toxic megacolon associated with antineoplastic chemotherapy: report of a case and review of the literature. Dis Colon Rectum 1992;35(4):369-372.
36. Thoeni RF, Cello JP. CT imaging of colitis. Radiology 2006;240(3):623-638.
37. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6): 559-568.
38. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008; 19(3):577-582.
39. Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14(2):135-141.
40. Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D. Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010;101(2): 180-183.
41. Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. Diagnosis of gastrointestinal graft-versus-host disease. Am J Gastroenterol 2000;95(11):3034-3038.
42. Schmit M, Bethge W, Beck R, Faul C, Claussen CD, Horger M. CT of gastrointestinal complications associated with hematopoietic stem cell transplantation. AJR Am J Roentgenol 2008;190(3): 712-719.
43. Dieckmann KP, Gehrckens R. Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma: a case report. BMC Cancer 2009;9:459.
44. Poirée S, Monnier-Cholley L, Tubiana JM, Arrivé L. Acute abdominal aortic thrombosis in cancer patients. Abdom Imaging 2004;29(4):511-513.
45. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27(29):4865-4873.
46. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16): 1232-1239.
47. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapyinduced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011;258(1): 41-56.
48. Pamuk GE, Taşçi M, Oztürk E, Demir M. Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. Med Oncol 2010;27(1):16-19.
49. Hecker A, Hecker B, Bassaly B, et al. Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. World J Surg Oncol 2010;8:47.
50. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radio Graphics 2006;26(2):481-495.
51. Munden RF, Erasmus JJ, Smythe WR, Madewell JE, Forster KM, Stevens CW. Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: an unusual CT appearance. AJR Am J Roentgenol 2005;184(4): 1091-1095.
52. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiationinduced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53(4): 810-821.
53. Khozouz RF, Huq SZ, Perry MC. Radiation-induced liver disease. J Clin Oncol 2008;26(29):4844-4845.
54. DeLappe EM, Truong MT, Bruzzi JF, Swisher SG, Rohren EM. Hepatic radiation injury mimicking a metastasis on positron-emission tomography/ computed tomography in a patient with esophageal carcinoma. J Thorac Oncol 2009;4 (11):1442-1444.
55. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29(1):9-18.
56. Berthrong M, Fajardo LF. Radiation injury in surgical pathology: Part II-alimentary tract. Am J Surg Pathol 1981;5(2):153-178.
57. Capps GW, Fulcher AS, Szucs RA, Turner MA. Imaging features of radiation-induced changes in the abdomen. RadioGraphics 1997;17(6):1455-1473.
58. Kalra MK, Maher MM, Boland GW, Saini S, Fischman AJ. Correlation of positron emission tomography and CT in evaluating pancreatic tumors: technical and clinical implications. AJR Am J Roentgenol 2003;181(2):387-393.
59. Charnsangavej C, Cinqualbre A, Wallace S. Radiation changes in the liver, spleen, and pancreas: imaging findings. Semin Roentgenol 1994;29(1): 53-63.
60. Libshitz HI, DuBrow RA, Loyer EM, Charnsangavej C. Radiation change in normal organs: an overview of body imaging. Eur Radiol 1996;6(6): 786-795.
61. Bendell J, Willett C. Upper gastrointestinal tract. In: Small W, Woloschak GE, eds. Radiation toxicity: practical medical guide (cancer treatment and research). New York, NY: Springer Science Business Media, 2006; 168.
62. Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995;31(5):1213-1236.
63. Letschert JG. The prevention of radiation-induced small bowel complications. Eur J Cancer 1995;31A (7-8):1361-1365.
64. Boudiaf M, Soyer P, Pelage JP, et al. CT of radiation induced injury of the gastrointestinal tract: spectrum of findings with barium studies correlation. Eur Radiol 2000;10(6):920-925.
65. Fishman EK, Zinreich ES, Jones B, Siegelman SS. Computed tomographic diagnosis of radiation ileitis. Gastrointest Radiol 1984;9(2):149-152.
66. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B; Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23(34): 8697-8705.
67. Schaefer O, Langer M. Detection of recurrent rectal cancer with CT, MRI and PET/CT. Eur Radiol 2007;17(8):2044-2054.
68. Ikushima H, Osaki K, Furutani S, et al. Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiationinduced pelvic insufficiency fractures. Gynecol Oncol 2006;103(3):1100-1104.
69. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56(1):83-88.
70. Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone: report of 11 cases. Cancer 1948;1 (1):3-29.
71. Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer. Radiology 2000;216(1):197-205.